Drug Profile
PTI 80
Alternative Names: Exebryl-1®; PTI-80Latest Information Update: 28 May 2018
Price :
$50
*
At a glance
- Originator ProteoTech
- Class Nootropics; Small molecules
- Mechanism of Action Amyloid beta-protein inhibitors; Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 May 2018 No recent reports of development identified for phase-I development in Alzheimer's-disease in USA (PO)
- 26 May 2016 This programme is still active
- 31 May 2012 Tianjin Tasly Pharmaceutical is now called Tasly Pharmaceutical Group